Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus

British Journal of Radiology

Volumn 85, Issue 1019, 2012, Pages

  Zhong, Z ^a   Gu, X ^a,b   Zhang, Z ^a   Wang, D ^a   Qing, Y ^a   Li, M ^a   Dai, N ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b 285th Hospital of the Chinese People's Liberation Army   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; RECOMBINANT ENDOSTATIN;

ADULT; AGED; ANEMIA; APPETITE DISORDER; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS STENOSIS; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LONG TERM CARE; LUNG EMBOLISM; MALE; METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; SHORT COURSE THERAPY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; ENDOSTATINS; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84868008831     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/15321801     Document Type: Review

References (25)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50. (Pubitemid 46655601)
2. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-7. (Pubitemid 29211772)
3. Shah MA, Schwartz GK. Treatment of metastatic esophagus and gastric cancer. Semin Oncol 2004;31:574-87. (Pubitemid 39089070)
4. Roder JD, Busch R, Stein HJ, Fink U, Siewert JR. Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg 1994;81:410-13. (Pubitemid 24124822)
5. Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000;6:1161-8. (Pubitemid 30159380)
6. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40. (Pubitemid 43108832)
7. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-6. (Pubitemid 46631363)
8. Folkman J, Camphausen K. Cancer. What does radiotherapy do to endothelial cells? Science 2001;293:227-8. (Pubitemid 32694723)
9. O'Reilly MS. Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol 2006;16:45-50. (Pubitemid 41832315)
10. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 2003;9:1957-71. (Pubitemid 36687614)
11. Safran H, Suntharalingam M, Dipetrillo T, Ng T, Doyle LA, Krasna M, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 2008;70:391-5.
12. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7. (Pubitemid 28027321)
13. Sun Y, Wang J, Liu Y, Song X, Zhang Y, Li K, et al. Results of phase III trial of rh-endostatin (YH-16) in advanced nonsmall cell lung cancer (NSCLC) patients. J Clin Oncol (Meeting Abstracts) 2005;23(16s):7138.
14. Itasaka S, Komaki R, Herbst RS, Shibuya K, Shintani T, Hunter NR, et al. Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys 2007;67:870-8. (Pubitemid 46215889)
15. Wen QL, Meng MB, Yang B, Tu LL, Jia L, Zhou L, et al. Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice. Cancer Sci 2009;100:1510-19.
16. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM. AJCC cancer staging manual. 6th edn. New York, NY: Springer-Verlag; 2002.
17. World Health Organization. World Health Organization handbook for reporting results of cancer treatment. WHO offset publication no. 48. Geneva, Switzerland: World Health Organization; 1979.
18. National Cancer Institute. Common terminology criteria for adverse events v. 3.0. Available from: http://ctep. cancer. gov/forms/CTCAEv3.pdf
19. Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Ishiyama H, et al. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato Digestive Disease & Oncology Group trial (KDOG 0501). Radiother Oncol 2008;87:398-404.
20. Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 2004;34:615-19. (Pubitemid 40662717)
21. Kaneko K, Ito H, Konishi K, Kurahashi T, Ito T, Katagiri A, et al. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer 2003;88:18-24. (Pubitemid 36241212)
22. Kuwahara A, Yamamori M, Nishiguchi K, Okuno T, Chayahara N, Miki I, et al. Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma. Int J Med Sci 2010;7:48-54.
23. Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999;17:2915-21. (Pubitemid 29415253)
24. Ohtsu A, Yoshida S, Boku N, Fujii T, Miyata Y, Hosokawa K, et al. Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Jpn J Clin Oncol 1995;25:261-6.
25. Safran H, Gaissert H, Akerman P, Hesketh PJ, Chen MH, Moore T, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001;19:1-7. (Pubitemid 32233795)